BrainScan.ai
AI decision-support software for brain CT interpretation, detecting and classifying brain pathologies.
Website: https://brainscan.ai/
Cover Block
PUBLIC
| Name | BrainScan.ai (BrainScan SA) |
| Tagline | AI decision-support software for brain CT interpretation, detecting and classifying brain pathologies. |
| Headquarters | Gdańsk, Poland |
| Founded | 2017 |
| Stage | Public |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | Eastern Europe |
| Growth Profile | Venture Scale |
| Founding Team | Kamil Bonc (Co-founder / CEO) [Perplexity Sonar Pro Brief] |
| Funding Label | Undisclosed (total disclosed ~$1,560,000) |
| Total Disclosed | ~$1.56M (2021) [CB Insights, 2026]; [BiznesRadar.pl, 2026] |
Links
PUBLIC
- Website: https://brainscan.ai/
- LinkedIn: https://www.linkedin.com/company/brainscan-ai/
- Financial Times Profile: https://markets.ft.com/data/equities/tearsheet/profile?s=BSN%3AWSE
Executive Summary
PUBLIC BrainScan.ai is a Polish medtech company applying specialized AI to the high-stakes problem of interpreting brain CT scans, a bet that has secured it a public listing and significant non-dilutive funding while most AI radiology startups remain private. Founded in 2017, the company has built a decision-support system that analyzes non-contrast head CTs, automatically detecting and classifying pathologies like hemorrhage to assist radiologists in emergency and neuroimaging workflows [Perplexity Sonar Pro Brief]. The product's narrow focus on brain CT, as opposed to broader multi-organ imaging, is its primary technical wedge, aiming for higher accuracy and a tighter fit with acute care settings like stroke and trauma [Perplexity Sonar Pro Brief]. Founder and CEO Kamil Bonc leads the company, which operates as BrainScan SA, though detailed background on the founding team is not widely covered in English-language sources. Its capital structure is a mix of undisclosed private venture rounds totaling at least $1.56 million and substantial public grants from Polish agencies, culminating in a 2024 listing on the Warsaw Stock Exchange's NewConnect market [CB Insights, 2026] [Financial Times / FT Markets, 2024]. Over the next 12-18 months, the key watchpoints are the translation of its public market status and grant capital into commercial traction with named hospital systems beyond its disclosed Polish deployments, and the scalability of its specialized model approach against broader-platform competitors.
Data Accuracy: YELLOW -- Core company facts are confirmed, but detailed founder backgrounds and specific commercial metrics are not independently corroborated in English-language sources.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Public |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Eastern Europe |
| Growth Profile | Venture Scale |
| Funding | Undisclosed (total disclosed ~$1,560,000) |
Company Overview
PUBLIC
BrainScan SA, operating as BrainScan.ai, was founded in 2017 in Gdańsk, Poland, as a medical technology company focused on a single, acute clinical problem. The company's public narrative centers on applying specialized artificial intelligence to non-contrast head CT scans, a high-volume imaging modality critical for stroke and trauma triage [CB Insights]. Its legal identity as a publicly traded entity, BrainScan SA, is a defining operational characteristic, with shares listed on the NewConnect market of the Warsaw Stock Exchange under the ticker BSN [Financial Times / FT Markets, 2024].
Key corporate milestones follow a trajectory from clinical validation to public market access. The company secured early validation in 2019 by winning a Gold Medal from the Radiological Society of North America (RSNA) for its AI solution for brain hemorrhage detection [BrainScan.ai]. Subsequent development was supported by significant non-dilutive capital, including a €2.5 million grant from the Polish Agency for Enterprise Development (PARP) and over €2.64 million in funding under the SMART Pathway program [BrainScan.ai]. The company transitioned to the public markets in 2024, a move noted by financial data providers but without disclosed offer specifics in widely available English sources [Multiples.vc, 2024].
Recent commercial activity indicates a shift from grant-funded R&D to deployment. In 2026, the company won a public tender to supply an educational system for brain CT analysis to a Polish healthcare center and signed an agreement to make its BrainScan CT software available through the global radiology platform CARPL.ai [BrainScan.ai, 2026] [Bankier.pl, 2026]. These steps represent the initial, publicly verifiable steps toward a commercial footprint beyond pilot installations, such as the previously noted deployment at the John Paul II Specialist Hospital in Cracow [BrainScan.ai].
Data Accuracy: YELLOW -- Core facts (founding, location, public status, key grants) are confirmed by the company and financial profiles. Specifics on the IPO process and detailed corporate history rely on limited English-language sources.
Product and Technology
MIXED BrainScan.ai's commercial offering is a narrowly focused AI decision-support system designed to interpret non-contrast head CT scans. The software automatically detects and classifies a range of common brain pathologies, including hemorrhage and lesions, flagging suspicious regions for a radiologist's review [Perplexity Sonar Pro Brief]. Company materials claim the system can identify 30 key pathologies, covering over 90% of findings in this imaging modality, with an average reported accuracy of 95% [BrainScan.ai]. The core value proposition is operational: by providing a consistent, automated read in approximately 10 seconds, the tool aims to support triage and prioritization of urgent cases in high-volume emergency and neuroimaging workflows, potentially reducing under-reporting of subtle findings [Perplexity Sonar Pro Brief].
The technology is positioned strictly as an assistive tool, not a replacement for radiologists. Integration with existing clinical infrastructure is a stated priority; the system is designed to deliver analysis results as infographics and structured text directly back to the Picture Archiving and Communication System (PACS) server from which the scan originated [MedImaging.net, 2026]. This focus on smooth workflow integration, rather than a standalone application, suggests a development philosophy centered on minimizing disruption in hospital radiology departments. The company's specific AI model architecture and training data composition are not publicly detailed, though the narrow focus on brain CT implies a more specialized approach than broader multi-organ imaging platforms.
Public validation of the product's technical capabilities includes a 2019 Gold Medal from the Radiological Society of North America (RSNA) for its AI solution for brain hemorrhage detection [BrainScan.ai]. More recent commercial validations include a deployment at the John Paul II Specialist Hospital in Cracow [BrainScan.ai] and a partnership announced in 2026 with CARPL.AI, a global digital radiology platform, to make BrainScan CT available through its offering [Bankier.pl, 2026]. The company also won a public tender in early 2026 to supply an educational system for brain CT scan analysis to a Polish healthcare center [BrainScan.ai, 2026].
Data Accuracy: GREEN -- Product claims and technical specifications are confirmed by the company's own website and corroborated by third-party medical imaging publications. Partnership and deployment announcements are sourced from company press releases and Polish financial news.
Market Research
PUBLIC The market for AI in medical imaging is defined by a persistent, acute shortage of specialized radiologists, a problem that has turned software from a productivity tool into a potential bottleneck-breaker in emergency care.
Third-party market sizing for AI-assisted brain CT interpretation specifically is not available in the structured research. However, the broader AI in medical imaging market provides a relevant analog. According to a Grand View Research report cited by competitor Qure.ai, the global AI in medical imaging market was valued at approximately $1.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 32.5% from 2024 to 2030 [Qure.ai]. This growth is anchored in several converging demand drivers. The global radiologist shortage is well-documented, with workload volumes increasing faster than the specialist workforce can expand. In acute neurological events like stroke, where time-to-treatment is directly correlated with patient outcomes, any tool that accelerates triage and initial read times carries significant clinical and economic value. BrainScan.ai's positioning targets this specific high-stakes workflow.
Key tailwinds extend beyond workforce gaps. Regulatory pathways for AI-based software as a medical device (SaMD) are becoming more defined in major markets like the United States and Europe, though they remain a complex and costly hurdle for market entry. Reimbursement models are also evolving, with some health systems beginning to establish codes for AI-assisted analyses, which is critical for sustainable commercialization. Furthermore, the digitization of healthcare infrastructure, including the widespread adoption of Picture Archiving and Communication Systems (PACS), creates a more integrable environment for decision-support software like BrainScan CT.
Adjacent and substitute markets highlight both opportunity and competitive pressure. The primary adjacent market is broader AI diagnostic support for other imaging modalities, such as chest X-rays or mammography, where several well-funded players operate. A key substitute is not another software product but the status quo: reliance on human radiologists alone, sometimes supplemented by teleradiology services to distribute workload. The commercial wedge for AI in this context must demonstrate not just parity with human reads but a measurable improvement in operational metrics, such as reduced turnaround time for urgent cases or a decrease in missed findings (under-reporting), to justify its cost.
Data Accuracy: YELLOW -- Market size is an analogous figure from a competitor citation; specific drivers are inferred from industry context rather than primary source claims.
Competitive Landscape
MIXED BrainScan.ai enters a specialized niche within the broader AI radiology market, competing on the depth of its brain CT focus rather than the breadth of its imaging coverage. The competitive map for AI-powered CT interpretation is increasingly crowded, but the company's strategy carves out a distinct position by concentrating exclusively on acute neurological conditions.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| BrainScan.ai | AI decision-support for brain CT, detecting and classifying 30+ pathologies for emergency triage. | Public (WSE), ~$1.56M private funding (2021), significant public grants. | Narrow, deep focus on non-contrast brain CT; integrates with PACS for workflow support; public listing provides capital structure clarity. | [CB Insights, 2026], [BrainScan.ai], [Financial Times / FT Markets, 2024] |
| Qure.ai | Broad AI radiology suite covering chest X-ray, head CT, and trauma CT across multiple body regions. | Venture-backed, $59M total funding (estimated). | Extensive product portfolio and global commercial footprint; strong published clinical validation across diverse geographies. | [CB Insights] |
The competitive environment can be segmented into three primary layers. First, broad-spectrum AI imaging platforms like Qure.ai offer head CT modules as part of a larger suite, appealing to health systems seeking a single vendor for multiple use cases. Second, incumbent PACS and imaging IT vendors are increasingly embedding AI capabilities into their workflows, potentially commoditizing point solutions. Third, a growing number of specialized neuro AI startups are emerging, though few have BrainScan.ai's public market status or its claimed specificity for over 30 brain pathologies [BrainScan.ai].
BrainScan.ai's current edge appears to be its specialization and regulatory traction. By focusing solely on brain CT, the company can develop models tuned to a specific clinical workflow, particularly stroke and trauma triage, which may yield performance advantages over generalist algorithms. Its Gold Medal from the Radiological Society of North America (RSNA) for hemorrhage detection provides a form of third-party validation [BrainScan.ai]. Furthermore, its success in securing substantial non-dilutive grant funding from Polish agencies (totaling over €5 million) and its public listing provide a capital structure that is less dependent on venture cycles, a potential durability factor in a capital-intensive sector [BrainScan.ai].
However, this narrow focus is also the company's primary exposure. It creates a single-point dependency on the brain CT market, leaving it vulnerable if broader platform vendors successfully bundle head CT AI into enterprise deals. A company like Qure.ai, with a larger sales force and a multi-modality product, could use its existing customer relationships to displace a niche player. BrainScan.ai's commercial footprint also appears concentrated in Poland, based on its disclosed hospital deployments and grant sources, raising questions about its ability to scale internationally against well-funded global competitors [BrainScan.ai, Bankier.pl, 2026].
The most plausible 18-month scenario hinges on distribution partnerships and clinical adoption. BrainScan.ai wins if it can use its recent agreement with the platform CARPL.AI to expand its reach beyond Poland and demonstrate superior clinical outcomes in head-to-head studies within its niche [Bankier.pl, 2026]. It loses share if integrated platform vendors successfully market their "good enough" head CT modules as part of hospital-wide AI procurement packages, making a standalone brain CT tool a harder sell for time-pressed radiology departments.
Data Accuracy: YELLOW -- Competitor data is limited; Qure.ai's funding and positioning are corroborated by industry databases, but detailed feature comparisons are not publicly available from neutral clinical sources.
Opportunity
PUBLIC
If BrainScan.ai can establish its AI as a standard-of-care tool for the initial triage of acute brain CT scans, the financial and clinical prize is a high-margin, recurring software business embedded in a global workflow with limited direct competition.
The headline opportunity is for BrainScan to become the default AI triage layer for emergency brain imaging in European and other single-payer healthcare systems. This outcome is reachable because the company has already cleared critical validation hurdles that are prerequisites for clinical adoption. It holds a Gold Medal from the Radiological Society of North America for its hemorrhage detection algorithm, a recognized industry benchmark [BrainScan.ai]. Its system is also deployed in at least one named Polish hospital, the John Paul II Specialist Hospital in Cracow, demonstrating a path to integration with real-world PACS infrastructure [BrainScan.ai]. The core product is narrowly focused on a high-volume, high-stakes clinical decision,interpreting non-contrast head CTs for stroke and trauma,which creates a clear, defensible wedge into radiology departments. Success here would position the company not as a generalist AI imaging vendor, but as the specialist tool hospitals turn to first for acute neurological cases.
Growth from this initial wedge could follow several concrete paths, each with identifiable catalysts.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| National Standard in Poland | BrainScan CT becomes the recommended or subsidized AI tool for head CT analysis across the Polish public health system. | A major tender win or a formal evaluation by the Polish Agency for Health Technology Assessment (AOTM). | The company has already secured significant non-dilutive grant funding from the Polish Agency for Enterprise Development (PARP) and won a public tender for an educational system in Kędzierzyn-Koźle [BrainScan.ai, 2026]. This suggests alignment with national health priorities and an existing procurement track record. |
| Platform Partnership Expansion | The software is distributed globally through partnerships with major PACS vendors or teleradiology platforms, moving beyond direct sales. | The announced agreement with CARPL.AI, a global digital radiology platform, leads to commercial deployments and similar deals with other platforms [Bankier.pl, 2026]. | The company's technology is described as integrating seamlessly with existing PACS servers [MedImaging.net, 2026], which is a key requirement for platform partners. The CARPL.AI deal provides a tangible test case for this channel. |
| Adjacency Expansion in Neurology | The company leverages its brain imaging data and clinical trust to launch AI tools for other neurological modalities, such as MRI or CT perfusion. | A product launch announcement for a new module, potentially funded by follow-on grant programs. | The company's foundational research project is titled "Multimodal system for automated diagnosis support," indicating a roadmap beyond standard CT [BrainScan.ai]. Deep specialization in the brain provides a logical foundation for expansion within neurology. |
Compounding for BrainScan would manifest as a clinical data and workflow moat. Each new hospital deployment generates additional, real-world scan data that can be used to refine the AI models, particularly for rare pathologies. This improves accuracy and reduces false positives, which in turn strengthens clinical trust and reduces radiologist resistance to adoption. Furthermore, integration into a hospital's emergency radiology workflow creates significant switching costs; once the AI is part of the standard triage protocol, replacing it would require retraining staff and revalidating clinical processes. Early signs of this flywheel are suggested by the company's claim of identifying 30 pathologies with 95% accuracy, a metric that likely required a substantial, curated dataset to achieve [BrainScan.ai].
The size of the win can be framed by looking at the market capitalization of publicly traded peers in the AI-assisted diagnostics space. While direct comparables are scarce, the valuation of BrainScan SA itself on the Warsaw Stock Exchange provides a baseline from which substantial upside could be realized if a growth scenario plays out. The company's stock has traded between 20.0 and 49.0 PLN [TradingView, 2026], reflecting its current status as a micro-cap company with early commercial traction. A successful execution of the "National Standard" scenario in Poland, a country of 38 million people, could support a valuation multiple more in line with profitable European healthtech SaaS businesses. For context, the broader AI in medical imaging market was valued at over $1 billion in recent years by various analyst firms, with neuroimaging representing a significant segment. If BrainScan captured a leading position in the European acute brain CT triage segment, a market cap an order of magnitude larger than its current trading range is a plausible outcome (scenario, not a forecast).
Data Accuracy: YELLOW -- The opportunity analysis is based on confirmed product claims, grant awards, and one partnership announcement, but the growth scenarios are forward-looking projections. The company's public market data provides a concrete valuation baseline.
Sources
PUBLIC
[Perplexity Sonar Pro Brief] BrainScan.ai Brief | https://www.perplexity.ai/
[CB Insights, 2026] BrainScan Company Profile | https://www.cbinsights.com/company/brainscanai
[BiznesRadar.pl, 2026] BrainScan SA Profile | https://www.biznesradar.pl/
[Financial Times / FT Markets, 2024] BrainScan SA, BSN:WSE profile | https://markets.ft.com/data/equities/tearsheet/profile?s=BSN%3AWSE
[BrainScan.ai] Home - BrainScan.ai | https://brainscan.ai/
[BrainScan.ai] BrainScan.AI Wins Global Recognition at RSNA - The World’s Top AI for Brain Hemorrhage Detection | https://brainscan.ai/brainscan-ai-wins-global-recognition-at-rsna-the-worlds-top-ai-for-brain-hemorrhage-detection/
[BrainScan.ai, 2026] BrainScan.AI Wins Tender for Educational System | https://brainscan.ai/
[MedImaging.net, 2026] BrainScan CT AI System | https://www.medimaging.net/
[Bankier.pl, 2026] BrainScan Signs Agreement with CARPL.AI | https://www.bankier.pl/
[Multiples.vc, 2024] Brainscan - Public Comps and Valuation Multiples | https://multiples.vc/public-comps/brainscan-valuation-multiples
[Qure.ai] Qure.ai Market Overview | https://qure.ai/
[TradingView, 2026] BrainScan SA (BSN) Stock Chart | https://www.tradingview.com/
Articles about BrainScan.ai
- BrainScan.ai's Polish AI for Brain CT Is Now a Public Company — The Warsaw-listed startup, backed by over €5 million in grants, is deploying its decision-support software for stroke and trauma scans in Polish hospitals.